Clinical efficacy of tamoxifen

ONCOLOGY

Volumn 11, Issue 2 SUPPL. 1, 1997, Pages 15-20

  Robert, Nicholas J ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; PREDNISONE; TAMOXIFEN; TAMOXIFEN CITRATE;

ADULT; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; FEMALE; HUMAN; MORTALITY; POSTMENOPAUSE; SURVIVAL;

ADJUVANTS, PHARMACEUTIC; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MALE; MENOPAUSE; TAMOXIFEN;

EID: 0031005807     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Jaiyesimi IA, Buzdar AU, Decker DA, et al: Use of tamoxifen for breast cancer: Twenty-eight years later. J Clin Oncol 13:513-529, 1995.
2. Robinson E, Kimmick GG, Muss HB: Tamoxifen in postmenopausal women: A safety perspective. Drugs & Aging 8:329-337, 1996.
3. Bilimoria MM, Assikis VJ, Jordan VC: Should adjuvant tamoxifen therapy be stopped at 5 years? Cancer J Sci Am 2:140-150, 1996.
4. Fisher B, Redmond C, Wickerham L, et al: Systemic therapy in patients with node-negative breast cancer: A commentary based on two National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials. Ann Intern Med 111:703-712, 1989.
5. Powles TJ, Jones AL, Ashley SE, et al: The Royal Marsden Hospital pilot tamoxifen chemopreventive trial. Breast Cancer Res Treat 31:73-83, 1994.
6. Vanchieri C, Breast cancer study initiated in Italy. J Natl Cancer Inst 84:1555-1556, 1992.
7. Consensus Development Panel: Adjuvant chemotherapy for breast cancer. JAMA 254:3461-3463, 1985.
8. Glick JH, Gelber RD, Goldhirsh A, et al: Meeting highlights: Adjuvant therapy for primary breast cancer. J Natl Cancer Inst 84:1479-1485, 1992.
9. Goldhirsh A, Wood WC, Senn H-J, et al: Meeting highlights: International Consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87:1441-1445, 1995.
10. Nolvadex Adjuvant Trial Organization: Controlled trial of tamoxifen as a single adjuvant agent in management of early breast cancer: Analysis at eight years by the Nolvadex Adjuvant Trial Organization. Br J Cancer 57:608-611, 1988.
11. Fisher B, Costantino J, Redmon C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med 320:479-484, 1989.
12. Fisher B, Costantino J, Wickerham L, et al: Adjuvant therapy for node negative breast cancer: an update of NSABP findings (abstract). Proc Am Soc Clin Oncol 12:A79, 1993.
13. Ribeiro G, Swindell R: The Christie Hospital adjuvant tamoxifen trial-status at 10 years Br J Cancer 57:601-603, 1988.
14. Breast Cancer Trials Committee, Scottish Cancer Trials Office: Adjuvant tamoxifen in the management of operable breast cancer: The Scottish trial. Lancet 2:171-175, 1987.
15. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: Part I. Lancet 339:1-15, 1992.
16. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy Part II. Lancet 339:71-85, 1992
17. Henderson IC: Endocrine therapy of metastic breast cancer, in Harris JR, Hellman S, Henderson IC, et al (eds): Breast Diseases, 2nd ed, pp 559-603. New York, Lippincott, 1991.
18. Kiang DT, Kennedy BJ: Tamoxifen (anti-estrogen) therapy in advanced breast cancer. Ann Intern Med 87:687-690, 1977.
19. Rose C, Mouridsen HT: Treatment of advanced breast cancer with tamoxifen: Recent results. Cancer Res 91:230-242, 1984.
20. Ingle JN, Mailliard JA, Schaid DJ, et al: A double-blind trial of tamoxifen plus placebo in postmenopausal women with metastatic breast cancer: A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Cancer 68:34-39, 1991.
21. Ingle JN, Ahmann DL, Green SJ, et al: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer N Engl J Med 304:16-21, 1981.
22. Manni A: Tamoxifen therapy of metastatic breast cancer. J Lab Clin Med 109:290-299, 1987.
23. Van Veelen H, Willemse PHB, Tjabbes T, et al: Oral high-dose medroxyprogesterone acetate versus tamoxifen: A randomized crossover trial in postmenopausal patients with advanced breast cancer. Cancer 58:7-13, 1986.
24. Castiglione-Gertsch M, Pampallona S, Varim M, et al: Primary endocrine therapy for advanced breast cancer. To start with tamoxifen or with medroxyprogesterone acetate. Ann Oncol 4:735-740, 1993.
25. Kimmick G, Muss HB: Current status of endocrine therapy for metastatic breast cancer. Oncology 9:877-890, 1995.
26. Ingle JN, Krook JE, Gren SJ, et al: Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4:178-185, 1986.
27. Buchanan RB, Blarney RW, Durrant KR, et al: A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4:1326-1330, 1986.
28. Cutuli B, Lacroze M, Dilhuydy JM, et al: Male breast cancer: Results of the treatments and prognostic factors in 397 cases. Eur J Cancer 31 A: 1960-1964, 1995.
29. Borgen P, Wong G, Vlarnis V, et al: Current management of male breast cancer: A review of 104 cases. Ann Surg 215:451, 1992.
30. Guinee VF, Moller T, Olsson H, et al: Clinical prognostic factors in male breast cancer: Eleven-center study, international cancer patient data exchange system (abstract). Proc Am Soc Clin Oncol 9:A138, 1990
31. Moore PM: Male breast cancer, in Harris JR, Lippman ME, Morrow M, et al(eds): Diseases of the Breast, pp 859-863. New York, Lippincott-Raven, 1996.
32. Caton J, Rearden T, Ellis R, Male breast cancer: the Department of Defense (DOD) experience (abstract). Proc Am Soc Clin Oncol 14:A140, 1995.
33. Ludwig Breast Cancer Study Group: Randomized trial of chemoendocrine therapy and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastases. Lancet 1:1256-1260, 1984.
34. Swedish Breast Cancer Cooperative Group: Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88:1543-1549, 1996.
35. Fisher B, Dignam J, Bryant J, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542, 1996.
36. Love RR, Mazess RB, Tormey DC, et al: Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 12:297-302, 1988.
37. Love RR, Mazess RB, Barden HS, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer N Engl J Med 326-852-856, 1992.
38. Fornander T, Rutqvist LE, Sjoberg HE, et al: Long-term adjuvant tamoxifen in early breast cancer: Effect on bone mineral density in postmenopausal women. J Clin Oncol 8:1019-1024, 1990.
39. Rutqvist LE, Matteson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85:1398-1406, 1993.
40. McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial: The Scottish Breast Cancer Committee. Br Med J 303:435-437, 1991.
41. Jordan VC, Morrow M: Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 30A:1714-1721, 1994.